Vertex Selects VX-659 and VX-445 for Two CF Triple Combo Regimens
Cystic Fibrosis
Vertex Pharmaceuticals has selected two of its next-generation correctors, VX-659 and VX-445, for Phase 3 trial development as part of two triple combination regimens for the treatment of cystic fibrosis. This ... Read more